Christine Lovly

Jun 1, 2024 | brnw.ch | Christine Lovly

Published In Journal of Clinical Oncology: JCO.24.00731HistoryPublished online: June 01, 2024PermissionsRequest permissions for this article. Clinical trial data can be requested by qualified researchers for use in rigorous, independent scientific research as long as the trials are not part of an ongoing or planned regulatory submission. Sharing of data is subject to protection of patient privacy and respect for the patient's informed consent.

May 31, 2024 | onclive.com | Christine Lovly

CommentaryVideoMay 31, 2024Author(s):Christine M. Lovly, MD, PhD, discusses the investigation of the EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer. Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center, discusses the investigation of the EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer (NSCLC).

May 13, 2024 | nature.com | Christine Lovly

In an era of expanding perioperative approaches for resectable non–small-cell lung cancer, new data demonstrate that dual neoadjuvant immunotherapy targeting PD-1 and LAG-3 is feasible; future analyses may enhance patient selection by identifying immune signatures predictive of response.

Mar 26, 2024 | nature.com | Pooja Middha |Michael Betti |Cosmin Bejan |Douglas Johnson |Linda Kachuri |Christine Lovly | +4 more

AbstractImmune checkpoint inhibitor-mediated colitis (IMC) is a common adverse event of treatment with immune checkpoint inhibitors (ICI). We hypothesize that genetic susceptibility to Crohn’s disease (CD) and ulcerative colitis (UC) predisposes to IMC.